# A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

> **NCT06629597** · PHASE3 · RECRUITING · sponsor: **MediLink Therapeutics (Suzhou) Co., Ltd.** · enrollment: 400 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** YL201
- **DRUG:** Docetaxel
- **DRUG:** Capecitabine
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT06629597
- **Lead sponsor:** MediLink Therapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-31
- **Primary completion:** 2027-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06629597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06629597, "A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06629597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*